We are live on ! Find out more
UBIO

Proshares UltraPro NASDAQ Biotechnology
UBIO

Delisted

UBIO was delisted on the 27th of March, 2020.

Back to rankings

2 hedge funds and large institutions have $2.06M invested in Proshares UltraPro NASDAQ Biotechnology in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

34,167% more capital invested

Capital invested by funds: $6K → $2.06M (+$2.05M)

0% more funds holding

Funds holding: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
$91K
Puts
–
Net Calls
+$91K
Net Calls Change
+$91K

Top Buyers

Rank Fund Capital Flow
1
BAMS
Bellevue Asset Management (Switzerland)
Switzerland
+$568K
2
UBS Group
UBS Group
Switzerland
+$31.6K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$4K
2
Morgan Stanley
Morgan Stanley
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BAMS
1
Bellevue Asset Management (Switzerland)
Switzerland
$2.04M +$568K +7,000 New
UBS Group
2
UBS Group
Switzerland
$17K +$31.6K +390 New
TRCT
3
Tower Research Capital (TRC)
New York
– -$4K -40 Closed
Morgan Stanley
4
Morgan Stanley
New York
– -$2K -17 Closed

UBIO Hedge Fund Activity: Q3 2015 in Review

2 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q3 2015, worth a combined $2.06M — up 34,167% from $6K a quarter earlier.

Fund positioning in UBIO was balanced in Q3 2015: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Bellevue Asset Management (Switzerland), opening a new position worth an estimated $568K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $4K sold.

  • 2 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $2.06M of Proshares UltraPro NASDAQ Biotechnology stock for Q3 2015, up 34,167% quarter-over-quarter.
  • 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q3 2015 and 2 closed out, a net change of 0 holders.
  • The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q3 2015 was Bellevue Asset Management (Switzerland), an estimated $568K added.
  • The largest Proshares UltraPro NASDAQ Biotechnology seller in Q3 2015 was Tower Research Capital (TRC), an estimated $4K sold.

Based on aggregated 13F filings for Q3 2015.